These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 18545836

  • 21. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
    Burgess DS, Hastings RW.
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
    [Abstract] [Full Text] [Related]

  • 22. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R.
    J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
    [Abstract] [Full Text] [Related]

  • 23. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.
    Chen YC, Chang SC, Shih CC, Hung CC, Luhbd KT, Pan YS, Hsieh WC.
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):175-83. PubMed ID: 10729660
    [Abstract] [Full Text] [Related]

  • 24. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW, Johnson EM, Rogers TR.
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [Abstract] [Full Text] [Related]

  • 25. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
    Li M, Liao Y, Chen M, Pan W, Weng L.
    Braz J Infect Dis; 2012 Sep; 16(2):175-9. PubMed ID: 22552461
    [Abstract] [Full Text] [Related]

  • 26. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
    Aller AI, Martín-Mazuelos E, Gutiérrez MJ, Bernal S, Chávez M, Recio FJ.
    J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
    [Abstract] [Full Text] [Related]

  • 27. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
    Franzot SP, Casadevall A.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
    [Abstract] [Full Text] [Related]

  • 28. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the Cryptococcus neoformans Complex in Jiangxi Province, South Central China.
    Yang C, Bian Z, Blechert O, Deng F, Chen H, Li Y, Yang Y, Chen M, Zhan P.
    Front Cell Infect Microbiol; 2021 Feb; 11():723251. PubMed ID: 34790585
    [Abstract] [Full Text] [Related]

  • 29. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
    Klepser ME, Wolfe EJ, Pfaller MA.
    J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
    [Abstract] [Full Text] [Related]

  • 30. Synergic effect of simvastatin in combination with amphotericin B against environmental strains of Cryptococcus neoformans from northeastern Brazil: a prospective experimental study.
    Silva THS, Araújo CV, Santos KMDC, Alves NDS, Gomes THS, Silva AKFE, Silva NCLDS, Damasceno Júnior ECB, Carvalho AMA, Mendes MGA, Caminha HB, Daboit TC, Ferreira TB, Andrade-Silva LE, Silva-Vergara ML, Ferreira-Paim K, Fonseca FM.
    Sao Paulo Med J; 2020 Mar; 138(1):40-46. PubMed ID: 32321104
    [Abstract] [Full Text] [Related]

  • 31. In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil.
    Alves SH, Oliveira LT, Costa JM, Lubeck I, Casali AK, Vainstein MH.
    Rev Inst Med Trop Sao Paulo; 2001 Mar; 43(5):267-70. PubMed ID: 11696849
    [Abstract] [Full Text] [Related]

  • 32. The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital.
    Aguiar PADF, Pedroso RDS, Borges AS, Moreira TA, Araújo LB, Röder DVDB.
    Rev Inst Med Trop Sao Paulo; 2017 Apr 13; 59():e13. PubMed ID: 28423088
    [Abstract] [Full Text] [Related]

  • 33. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
    Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM.
    Rev Iberoam Micol; 2009 Sep 30; 26(3):194-7. PubMed ID: 19635445
    [Abstract] [Full Text] [Related]

  • 34. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC, de Paula DA, Dutra V, Nakazato L, Tadano T, Lazera Mdos S, Wanke B, Trilles L, Walderez Szeszs M, Silva D, Hahn RC.
    J Infect Dev Ctries; 2014 Aug 13; 8(8):1037-43. PubMed ID: 25116671
    [Abstract] [Full Text] [Related]

  • 35. Comparative evaluation of Fungitest-, Neo-Sensitabs- and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans.
    Swinne D, Raes-Wuytack C, Van Looveren K, Desmet P.
    Mycoses; 1999 Aug 13; 42(4):231-7. PubMed ID: 10424089
    [Abstract] [Full Text] [Related]

  • 36. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E, Vitali LH, Kress MRVZ, Martinez R.
    Rev Inst Med Trop Sao Paulo; 2017 Aug 13; 59():e49. PubMed ID: 28793019
    [Abstract] [Full Text] [Related]

  • 37. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.
    J Antimicrob Chemother; 2005 Dec 13; 56(6):1144-7. PubMed ID: 16282208
    [Abstract] [Full Text] [Related]

  • 38. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
    Souza LK, Souza Junior AH, Costa CR, Faganello J, Vainstein MH, Chagas AL, Souza AC, Silva MR.
    Mycoses; 2010 Jan 13; 53(1):62-7. PubMed ID: 19500261
    [Abstract] [Full Text] [Related]

  • 39. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.
    Poonwan N, Mikami Y, Poosuwan S, Boon-Long J, Mekha N, Kusum M, Yazawa K, Tanaka R, Nishimura K, Konyama K.
    Eur J Epidemiol; 1997 Apr 13; 13(3):335-40. PubMed ID: 9258534
    [Abstract] [Full Text] [Related]

  • 40. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA, Arthur I, Merritt A, Leung M.
    Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.